Abstract
OspA (outer surface protein A) is an abundant immunogenic lipoprotein of the Lyme disease spirochete Borrelia burgdorferi. The crystal structure of a soluble recombinant form of OspA was solved in a complex with the Fab fragment of mouse monoclonal antibody 184.1 and refined to a resolution of 1.9 Å. OspA has a repetitive antiparallel β topology with an unusual nonglobular region of “freestanding” sheet connecting globular N- and C-terminal domains. Arrays of residues with alternating charges are a predominant feature of the folding pattern in the nonglobular region. The 184.1 epitope overlaps with a well conserved surface in the N-terminal domain, and a hydrophobic cavity buried in a positively charged cleft in the C-terminal domain is a potential binding site for an unknown ligand. An exposed variable region on the C-terminal domain of OspA is predicted to be an important factor in the worldwide effectiveness of OspA-based vaccines.
Lyme disease is a progressive infection resulting from inoculation of the spirochete Borrelia burgdorferi into the skin by a feeding tick, usually Ixodes species (1). Dissemination occurs early and can produce a wide array of clinical manifestations. Because some individuals are initially asymptomatic, there is no objective sign or laboratory abnormality that can universally identify infection. Left untreated, infection can eventually lead to serious joint, neurologic, cardiac, and skin abnormalities.
Two basic lipoproteins with 53% sequence identity are abundant proteins of cultured B. burgdorferi spirochetes (2). OspA (outer surface protein A, 31 kDa) and OspB (34 kDa) are encoded by tandem genes located on a 49-kb linear plasmid and are transcribed in a single transcriptional unit (3, 4); their natural biological functions are unknown. Although several studies suggest that the predominant location of these antigens is periplasmic, they are also found on the fluid outer membrane (5–8). OspA has been shown to be present when the spirochete is dormant in the tick midgut but is no longer detected after rapid division and dissemination to the tick salivary glands during a blood meal (9). This may explain why the natural immune response to OspA develops only in a minority of Lyme disease patients, and usually only late in the course of the disease. Preliminary studies have shown that vaccines based on OspA can induce protective immunity in mammals (10–12). Blockage of spirochete transmission from the tick vector to the mammalian host by anti-OspA antibodies appears to be the main mechanism of protection (13). Phase III trials to assess the effectiveness of recombinant OspA vaccines in humans are in progress (14, 15).
A fully successful vaccine will require delineation of neutralizing epitopes of OspA and their variation across the range of Lyme-disease-causing Borrelia (16, 17). We initiated structure determination of OspA (from strain B31) to aid in vaccine design and to begin to elucidate protein function. Although OspA normally has a lipidated N-terminal cysteine to provide a membrane anchor (18), a recombinant unlipidated form is soluble in aqueous solution and is still recognized by antibodies from Lyme disease patients (19). Efforts to crystallize recombinant OspA by itself failed, but crystals of the protein complexed with the antigen-binding fragment of a murine monoclonal antibody (Fab 184.1) were readily obtained (20). The structure was solved by a combination of molecular replacement and multiple isomorphous replacement methods using diffraction data collected with synchrotron radiation (see Table 1 for details). We report herein a refined atomic model for the complex at a resolution of 1.9 Å (see Fig. 1 for refinement details). OspA has a number of intriguing features, including a novel folding pattern that incorporates alternating charge arrays into antiparallel β-sheet, a potential ligand binding site, a conserved surface overlapping the epitope of the Fab, and a distinctive variable motif. We suggest that the protein has a conserved function, possibly acting as a receptor or signal transducer.
Table 1.
Dataset | Cys-84-I | Cys-84-II | K2PtCl4 | KI | Pb(CH3)3 |
---|---|---|---|---|---|
Observed reflections, no. | 155,965 | 254,719 | 87,304 | 70,488 | 89,601 |
Unique reflections, no. | 36,731 | 58,870 | 20,837 | 17,419 | 23,461 |
Resolution limit, Å | 2.30 | 1.95 | 2.80 | 2.85 | 2.70 |
Completeness, %* | 97.9 (86.4) | 97.1 (88.3) | 98.2 (96.9) | 88.5 (91.0) | 99.3 (99.0) |
Rmerge, %† | 5.2 (22.4) | 4.8 (21.6) | 8.0 (21.7) | 8.6 (19.5) | 6.9 (23.2) |
Riso, %† | 6.8 | 10.5 | 6.6 | ||
Phasing power‡ | 1.61 (1.69) | 1.24 | 1.09 (1.37) |
Data for reflections in the last shell for the given resolution limit are in parentheses. The shell width is ≈0.1 Å.
Rmerge indicates agreement of individual reflection measurements over the set of unique averaged reflections: Rmerge = Σh Σi |I(h)i − I(h)|/Σh Σi I(h)i, where h is the Miller index and i indicates individual observed reflections, including those in symmetry equivalent positions. Riso indicates agreement of native and derivative structure factures: Riso = Σh |FP(h) − FPH(h)|/Σh FP(h).
Phasing power is the mean heavy-atom structure factor amplitude divided by the mean lack-of-closure error. Larger values usually indicate better calculated experimental phases. For platinum and lead derivatives, the phasing power for the anomalous component is given in parentheses.
MATERIALS AND METHODS
OspA–Fab 184.1 crystals were grown by vapor diffusion as described (20); they belong to space group P212121, with unit cell dimensions a = 89.2 Å, b = 91.7 Å, and c = 100.8 Å. Diffraction data (Table 1) were collected at the Brookhaven National Laboratory National Synchrotron Light Source, on beamlines X25 (Cys-84-II) and X12C (all others). Each data set was collected from a single crystal soaked for 1–2 days in a cryoprotectant solution [50 mM Tris·HCl, pH 8.5/80 mM MgCl2/20% PEG (Mr 3300)/8% glycerol] and then flash-cooled to 100 K. Platinum and lead derivatives were obtained by presoaking crystals in stabilizing solutions (no glycerol) containing millimolar concentrations of the heavy atom compounds; the iodine derivative was obtained by reacting the OspA–Fab 184.1 complex with Iodo-beads (Pierce) prior to crystallization. Diffraction images were collected using MAR image plate/scanner systems and were processed with denzo (22).
When the HyHEL5 Fab (23) was used as a search model, a molecular replacement solution was independently obtained with both amore (24) and xplor (25–27). Phases calculated with the single platinum site identified by isomorphous and anomalous difference Patterson functions were employed to locate lead and iodine derivative sites; molecular replacement phased difference Fouriers provided independent verification of derivative sites. Several cycles of phase combination with sigmaa (28), solvent flattening with solomon (29), model building with o (30), followed by refinement with xplor were then performed. The assignment of side chains for the OspA polypeptide [strain B31 sequence (31)] was confirmed by difference Fourier maps locating the positions of two OspA site-directed point mutants (Ser-84 → Cys and Ser-116 → Cys: wild-type sequence and Cys-116 mutant data sets were collected but are not reported in Table 1). Diffraction data sets from OspA Cys-84 mutant crystals were of higher quality than those of native OspA and so were ultimately used as parents in phasing calculations. The platinum compound bound to the sole methionine residue of OspA (Met-38); six iodine positions were located on tyrosine phenol rings of the Fab.
Recombinant OspA lacks the hydrophobic leader and signal peptidase II site of the native protein precursor (19). Ala-17, the mature recombinant N-terminal residue, replaces the mature native lipidated N-terminal Cys-17; the remainder of the recombinant polypeptide follows the OspA sequence (31). Electron density is not observed for the first six residues, so the OspA model extends from Ser-23 to Lys-273, the C terminus. The Fab model was generated by replacing the molecular replacement model with an immunoglobulin of class G2b and then making substitutions according to Fab 184.1 light and heavy chain gene sequences that were determined by N-terminal sequencing followed by a reverse transcriptase-coupled polymerase chain reaction/sequencing method (Novagen). The final R factor for the OspA–Fab complex model refined against dataset Cys-84-II is 22.9% (R-free = 29.5%), with 5498 nonhydrogen atoms, including 328 water oxygens.
RESULTS AND DISCUSSION
Previous biophysical studies by France et al. (32) predicted predominantly β-structure for OspA. In the crystalline OspA–Fab 184.1 complex, OspA is folded into 21 consecutive antiparallel β-strands connected by turns or short loops, followed by a single C-terminal α-helix (Figs. 1 and 2). Ten β-strands (5–14n) form the molecule’s scaffold: a long central β-sheet with right-handed twist. One edge of the central sheet is well-ordered with tight turns; the other edge is more poorly ordered with longer loops and β-bulges near the ends of three strands (Figs. 2 and 3). The repetitive fold of the central sheet is reminiscent of repetitive nonglobular structures—e.g., coiled-coils and leucine zippers. We designate the two faces of the central sheet as “front” and “back.” A small N-terminal β-sheet (strands 1–4) packs perpendicular to the first four strands of the front face, forming a β-sandwich domain. At the C-terminal end, two β-sheets (strands 14c–16 and 17–21) straddle the final α-helix to form a barrel-like unit that packs against the last five strands of the back face. Although the central sheet is involved in typical globular domain-packing arrangements at either end, three β-strands in the center (strands 8–10) are largely exposed to solvent on both faces. The latter feature appears to be unique among known protein structures; the distribution of residues in this region warrants careful inspection. OspA may prove to be a useful model for study of the folding of freestanding antiparallel β-sheets.
A large electrostatic component to the folding of recombinant OspA had been predicted based on the unusual stability of the protein at low and high salt concentrations and over a wide pH range (32). In our model, all but three of 74 charged residues have surface-exposed charged groups forming ion pairs or higher-order arrays (the three exceptions are discussed later). An extended charge array composed of six side chains of alternating Glu and Lys residues is found on the back face of the central sheet, and an interrupted charge array (Lys, Glu, Ile, Glu, Lys, Glu) sits in an adjacent position on the front face (see Fig. 2, residues in italics). This arrangement bears resemblance to polar zippers predicted by Perutz and colleagues (33, 34) for primary sequences containing more obvious and extended regions of alternating charges. Although charged residues are known to be poor at forming antiparallel β-sheets by themselves, ion pairs across antiparallel β-strands have favorable side-chain interaction energies (35). Residues known to favor β-sheet formation, hydrophobic and uncharged polar residues (36, 37), flank the charge arrays. Alignment of available OspA and OspB sequences (see Fig. 4) suggests that the charge arrays are not strictly conserved but continuous runs with four or more alternating charges always appear on at least one of the two faces. Charge arrays are likely to be an important feature in the stability of the central sheet antiparallel folding motif.
Monoclonal antibody 184.1 was raised against sonicated spirochetes (40). It recognizes an epitope near the N terminus of OspA that is not readily accessible on intact spirochetes (41). The Fab 184.1–OspA interface is typical of Fab–protein complexes (42), with extensive surface burial (800 Å2 for OspA and 1200 Å2 for the Fab), and intermolecular contacts that include seven direct hydrogen bonds, two ion pairs, numerous van der Waal’s interactions, and water bridges. Consistent with the broad specificity of monoclonal antibody 184.1 (43), the epitope overlaps a highly conserved surface of OspA (Figs. 2 and 4). The size, shape, and in vivo inaccessibility of the conserved surface suggests that this region of OspA may normally take part in a specific interaction with another membrane component.
The C-terminal domain is the target of most agglutinating and neutralizing antibodies directed against OspA (44, 45); it must therefore be accessible on the spirochete cell surface. Mapping studies with OspA point mutants (46) have shown that the epitopes of three strain-specific agglutinating monoclonal antibodies as well as one broader-specificity neutralizing monoclonal antibody overlap a variable region in the C-terminal domain that includes a strictly conserved tryptophan residue (Trp-216). This region was predicted to adopt an α-helical conformation (47), but instead it encompasses two β-strands, 16 and 17, plus the loops flanking these strands (see Figs. 2 and 4). The discontinuity in main-chain hydrogen-bond formation between β-strands 16 and 17 provides significant surface exposure to most of the residues, a feature that might predispose the region to be antigenic. Conserved residues, including Trp-216, face inward to form interstrand contacts. Residues that vary widely across the five defined genospecies of Lyme-disease-causing Borrelia (though are fairly well conserved within genospecies) are either outward-facing at the centers β-strands 16 and 17 or are exposed in the three loops flanking the two strands (Fig. 2). Significantly, the epitope of the protective monoclonal antibody LA-2 (48, 49) has recently been mapped to this hypervariable region (50). Success of recombinant OspA as a protective vaccine in a hamster model is strongly correlated with high titers of LA-2-equivalent antibodies (51). Thus, vaccines based on OspA may require representatives of this hypervariable region from several genospecies for world-wide effectiveness. To better define the epitope of LA-2, we have obtained crystals of OspA complexed with the LA-2 Fab fragment and structure determination is underway.
A prominent feature of the center of the C-terminal barrel domain is a trio of partially buried charged residues–Arg-139 from β-strand 10, Glu-160 from β-strand 12, and Lys-189 from β-strand 15 (Fig. 5). Of the three residues, the first two are strictly conserved in both OspA and OspB; position 189 is nearly always Lys in OspA and Arg in OspB. The trio is situated at the base of a well-conserved prominent cleft ≈5 Å across, 24 Å long, and 8 Å deep. The cleft is formed in the C-terminal domain and is extended by curling of poorly ordered loops of the central sheet toward the back face, an effect promoted by β-bulges near the ends of β-strands 8, 10, and 11. The aliphatic side-chain methylenes of Lys-189 form the “lid” of a 34-Å3 solvent-inaccessible cavity that is lined by well-conserved hydrophobic residues (Fig. 5). Even though the cavity is large enough in volume to accommodate two solvent molecules, electron density maps do not indicate preferred water positions. The presence of the cavity and partially buried charges within the cleft suggests that the C-terminal domain of OspA might be a binding site for a ligand that could have a negative charge and certainly some hydrophobic character. We can only guess at the nature of the ligand, but the cleft is large enough to fit a small peptide, linear saccharide, or an exposed protein loop. Three-dimensional search programs (52–54) using either the whole OspA structure or the Arg-139, Glu-160, and Lys-189 motif as probes failed to find a similar arrangement of partially buried charged residues in other known protein structures.
We have described herein the structure of a protein of immunological interest for which there is no defined function. The usual question asked at the end of a structure determination, which is how does structure explain function, must be turned around–what does structure tell us about possible function? Although OspA has no significant sequence or structural homology to proteins with known function, we can still draw in a general way on known structure–function relationships. An extensive conserved surface usually denotes interactions with other macromolecules, and the presence of conserved charged groups in a pronounced cleft is typical of proteins that bind small or linear polymeric ligands. In its natural position in the spirochete, OspA could thus play a sensory role, e.g., recognizing either a soluble or host cell surface biomolecule in its C-terminal cleft and transmitting this information to another membrane component.
Acknowledgments
We are grateful to A. G. Murzin for recognizing the repetitive β-hairpin motif and pointing out the work of M. Perutz on polar zippers; P. Artymiuk and G. Vriend for performing three-dimensional homology searches; P. Freimuth for help with sequencing the Fab 184.1 genes; R. M. Sweet, M. S. Capel, and L. Berman for assistance at the National Synchrotron Light Source beamlines X12-C and X25; the National Cell Culture Center (Minneapolis) for antibody production; and F. T. Burling and V. L. Rath for discussions and helpful suggestions. The National Synchrotron Light Source is supported by the U.S. Department of Energy Office of Basic Energy Sciences. This research was conducted at Brookhaven National Laboratory with the support of the National Institutes of Health (Grant RO1-AI37256), Brookhaven National Laboratory (Laboratory Directed Research and Development Grant 94-32), and the U.S. Department of Energy Office of Health and Environmental Research.
ABBREVIATION
- OspA
outer surface protein A
Footnotes
Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, Biology Department, Brookhaven National Laboratory, Upton, NY 11973 (reference 1OSP).
References
- 1.Barbour A G, Fish D. Science. 1993;260:1610–1616. doi: 10.1126/science.8503006. [DOI] [PubMed] [Google Scholar]
- 2.Barbour A G, Tessier S L, Todd W J. Infect Immun. 1983;41:795–804. doi: 10.1128/iai.41.2.795-804.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Howe T R, Mayer L W, Barbour A G. Science. 1985;227:645–646. doi: 10.1126/science.3969554. [DOI] [PubMed] [Google Scholar]
- 4.Howe T R, LaQuier F R, Barbour A G. Infect Immun. 1986;54:207–212. doi: 10.1128/iai.54.1.207-212.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Brusca J S, McDowall A W, Norgard M V, Radolf J D. J Bacteriol. 1991;173:8004–8008. doi: 10.1128/jb.173.24.8004-8008.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Skare J T, Shang E S, Foley D M, Blanco D R, Champion C I, Mirzabekov T, Sokolov Y, Kagan B L, Miller J N, Lovett M A. J Clin Invest. 1995;96:2380–2392. doi: 10.1172/JCI118295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Radolf J D, Goldberg M S, Bourell K, Baker S I, Jones J D, Norgard M V. Infect Immun. 1995;63:2154–2163. doi: 10.1128/iai.63.6.2154-2163.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Carroll J A, Gherardini F C. Infect Immun. 1996;64:392–398. doi: 10.1128/iai.64.2.392-398.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Schwan T G, Piesman J, Golde W T, Dolan M C, Rosa P A. Proc Natl Acad Sci USA. 1995;92:2909–2913. doi: 10.1073/pnas.92.7.2909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fikrig E, Barthold S W, Kantor F S, Flavell R A. Science. 1990;250:553–556. doi: 10.1126/science.2237407. [DOI] [PubMed] [Google Scholar]
- 11.Fikrig E, Barthold S W, Persing D H, Sun X, Kantor F S, Flavell R A. J Immunol. 1992;148:2256–2260. [PubMed] [Google Scholar]
- 12.Langermann S, Palaszynski S, Sadziene A, Stover C K, Koenig S. Nature (London) 1994;372:552–556. doi: 10.1038/372552a0. [DOI] [PubMed] [Google Scholar]
- 13.de Silva A M, Telford S R, III, Brunet L R, Barthold S W, Fikrig E. J Exp Med. 1996;183:271–275. doi: 10.1084/jem.183.1.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Stover C K, Bansal G P, Hanson M S, Burlein J E, Palaszynski S R, Young J F, Koenig S, Young D B, Sadziene A, Barbour A G. J Exp Med. 1993;178:197–209. doi: 10.1084/jem.178.1.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Keller D, Koster F T, Marks D H, Hosbach P, Erdile L F, Mays J P. J Am Med Assoc. 1994;271:1764–1768. [PubMed] [Google Scholar]
- 16.Baranton G, Postic D, Saint Girons I, Boerlin P, Piffaretti J C, Assous M, Grimont P A. Int J Syst Bacteriol. 1992;42:378–383. doi: 10.1099/00207713-42-3-378. [DOI] [PubMed] [Google Scholar]
- 17.Postic D, Assous M V, Grimont P A, Baranton G. Int J Syst Bacteriol. 1994;44:743–752. doi: 10.1099/00207713-44-4-743. [DOI] [PubMed] [Google Scholar]
- 18.Brandt M E, Riley B S, Radolf J D, Norgard M V. Infect Immun. 1990;58:983–991. doi: 10.1128/iai.58.4.983-991.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Dunn J J, Lade B N, Barbour A G. Protein Expression Purif. 1990;1:159–168. doi: 10.1016/1046-5928(90)90011-m. [DOI] [PubMed] [Google Scholar]
- 20.Li H, Lawson C L. J Struct Biol. 1995;115:335–337. doi: 10.1006/jsbi.1995.1058. [DOI] [PubMed] [Google Scholar]
- 21.Evans S V. J Mol Graphics. 1993;11:134–138. doi: 10.1016/0263-7855(93)87009-t. [DOI] [PubMed] [Google Scholar]
- 22.Otwinowski Z. In: Proceedings of the CCP4 Study Weekend: Data Collection and Processing. Sawyer L, Isaacs N, Bailey S, editors. Daresbury Laboratory, Warrington, U.K.: Science and Engineering Research Council; 1993. pp. 56–62. [Google Scholar]
- 23.Sheriff S, Silverton E W, Padlan E A, Cohen G H, Smith-Gill S J, Finzel B C, Davies D R. Proc Natl Acad Sci USA. 1987;84:8075–9079. doi: 10.1073/pnas.84.22.8075. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Navaza J. Acta Crystallogr A. 1994;50:157–163. [Google Scholar]
- 25.Brünger A T, Kuriyan J, Karplus M. Science. 1987;235:458–460. doi: 10.1126/science.235.4787.458. [DOI] [PubMed] [Google Scholar]
- 26.Brünger A T. Acta Crystallogr A. 1990;46:46–57. doi: 10.1107/s0108767390002355. [DOI] [PubMed] [Google Scholar]
- 27.Brünger A T. Nature (London) 1992;335:472–475. doi: 10.1038/355472a0. [DOI] [PubMed] [Google Scholar]
- 28.Read R J. Acta Crystallogr A. 1986;42:140–149. [Google Scholar]
- 29.Abrahams J P, Leslie A G W, Lutter R, Walker J E. Nature (London) 1994;370:621–628. doi: 10.1038/370621a0. [DOI] [PubMed] [Google Scholar]
- 30.Jones T A, Zou J Y, Cowan S W, Kjeldgaard M. Acta Crystallogr A. 1991;47:110–119. doi: 10.1107/s0108767390010224. [DOI] [PubMed] [Google Scholar]
- 31.Bergström S, Blundoc V G, Barbour A G. Mol Microbiol. 1989;3:479–486. doi: 10.1111/j.1365-2958.1989.tb00194.x. [DOI] [PubMed] [Google Scholar]
- 32.France L L, Kieleczawa J, Dunn J J, Hind G, Sutherland J C. Biochim Biophys Acta. 1992;1120:59–68. doi: 10.1016/0167-4838(92)90424-c. [DOI] [PubMed] [Google Scholar]
- 33.Perutz M F, Staden R, Moens L, De Baere I. Curr Biol. 1993;3:249–253. doi: 10.1016/0960-9822(93)90174-m. [DOI] [PubMed] [Google Scholar]
- 34.Perutz M F. Protein Sci. 1994;3:1629–1637. doi: 10.1002/pro.5560031002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Smith C K, Regan L. Science. 1995;270:980–982. doi: 10.1126/science.270.5238.980. [DOI] [PubMed] [Google Scholar]
- 36.Kim C A, Berg J M. Nature (London) 1993;362:267–270. doi: 10.1038/362267a0. [DOI] [PubMed] [Google Scholar]
- 37.Minor D L, Jr, Kim P S. Nature (London) 1994;367:660–663. doi: 10.1038/367660a0. [DOI] [PubMed] [Google Scholar]
- 38.Barton G J. Protein Eng. 1993;6:37–40. doi: 10.1093/protein/6.1.37. [DOI] [PubMed] [Google Scholar]
- 39.Honig B, Nicholls A. Science. 1995;268:1144–1149. doi: 10.1126/science.7761829. [DOI] [PubMed] [Google Scholar]
- 40.Jiang W, Luft B J, Munoz P, Dattwyler R J, Gorevic P D. J Immunol. 1990;144:284–289. [PubMed] [Google Scholar]
- 41.Schubach W H, Mudri S, Dattwyler R J, Luft B J. Infect Immun. 1991;59:1911–1915. doi: 10.1128/iai.59.6.1911-1915.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Davies D R, Cohen G H. Proc Natl Acad Sci USA. 1996;93:7–12. doi: 10.1073/pnas.93.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Jiang W, Gorevic P D, Dattwyler R J, Dunn J J, Luft B J. Clin Diagn Lab Immunol. 1994;1:406–412. doi: 10.1128/cdli.1.4.406-412.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wilske B, Luft B J, Schubach W H, Zumstein G, Jauris S, Preac-Mursic V, Kramer M D. Med Microbiol Immunol. 1992;181:191–207. doi: 10.1007/BF00215765. [DOI] [PubMed] [Google Scholar]
- 45.Sears J E, Fikrig E, Nakagawa T Y, Deponte K, Marcantonio N, Kantor F S, Flavell R A. J Immunol. 1991;147:1995–2000. [PubMed] [Google Scholar]
- 46.McGrath B C, Dunn J J, Gorgone G, Guttman D, Dykhuizen D, Luft B J. Infect Immun. 1995;63:1356–1361. doi: 10.1128/iai.63.4.1356-1361.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.France L L, Kieleczawa J, Dunn J J, Luft B J, Hind G, Sutherland J C. Biochim Biophys Acta. 1993;1202:287–296. doi: 10.1016/0167-4838(93)90018-m. [DOI] [PubMed] [Google Scholar]
- 48.Schaible U E, Kramer M D, Eichmann K, Modolell M, Museteanu C, Simon M M. Proc Natl Acad Sci USA. 1990;87:3768–3772. doi: 10.1073/pnas.87.10.3768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Simon M M, Schaible U E, Kramer M D, Eckerskorn C, Museteanu C, Muller-Hermelink H K, Wallich R. J Infect Dis. 1991;164:123–132. doi: 10.1093/infdis/164.1.123. [DOI] [PubMed] [Google Scholar]
- 50.Rubenbauer, F. V. (1996) Masters thesis (C. W. Post College, Long Island University, Brookville, NY).
- 51.Johnson B J B, Sviat S L, Happ C M, Dunn J J, Frantz J C, Mayer L W, Piesman J. Vaccine. 1995;13:1086–1094. doi: 10.1016/0264-410x(95)00035-y. [DOI] [PubMed] [Google Scholar]
- 52.Holm L, Sander C. Trends Biochem Sci. 1995;20:478–480. doi: 10.1016/s0968-0004(00)89105-7. [DOI] [PubMed] [Google Scholar]
- 53.Artymiuk P J, Poirrette A R, Grindley H M, Rice D W, Willett P. J Mol Biol. 1994;243:327–344. doi: 10.1006/jmbi.1994.1657. [DOI] [PubMed] [Google Scholar]
- 54.Vriend G. J Mol Graphics. 1990;8:52–56. doi: 10.1016/0263-7855(90)80070-v. [DOI] [PubMed] [Google Scholar]